Objective This study was designed to investigate whether plasma concentration of cardiotrophin-1 (CT-1), a cytokine that induces cardiomyocyte hypertrophy and stimulates cardiac fibroblasts, is related to hypertensive heart disease, as defined by the presence of echocardiographically assessed left ventricular hypertrophy (LVH).
Introduction
The essential criterion in defining hypertensive heart disease is the presence of left ventricular hypertrophy (LVH) in the absence of a cause other than arterial hypertension. It is now accepted that besides cardiomyocyte growth, an exaggerated deposition of collagen fibers leading to myocardial fibrosis also contributes to LVH in arterial hypertension [1] . Hypertensive LVH develops in response to stress pathways activated by the mechanical overload imposed by systemic hypertension on the left ventricle. It has been proposed that some of these pathways involve the participation of gp 130-dependent ligands [2] .
Cardiotrophin-1 (CT-1) is a 201 amino acid member of the interleukin-6 superfamily [3] , which binds to glycoprotein 130 (gp130) and the leukemia inhibitory factor (LIF) receptor, a component of the gp130 receptor family [4] . At the cardiac level, CT-1 is synthesized and secreted by both cardiomyocytes and non-cardiomyocytes [5] . Whereas in vitro findings suggest that CT-1 has growth- [6, 7] and survival-promoting properties in cardiomyocytes [8] , in vivo studies have shown that systemic administration of CT-1 is associated with cardiac hypertrophy [9] . It has been reported that ventricular CT-1 gene expression is increased in spontaneously hypertensive rats (SHR) in the early stage of LVH and it remains elevated after hypertrophy has developed [10, 11] . Furthermore, cardiac levels of CT-1 mRNA and protein are increased in Dahl salt-sensitive hypertensive rats with LVH compared with Dahl salt-resistant normotensive rats [12] . On the other hand, the presence of CT-1, its receptors and signaling pathways has been demonstrated at gene and protein level in cardiac fibroblasts [5, [13] [14] [15] . In addition, it has been shown that CT-1 directly stimulates proliferation and collagen type I synthesis in this cell type [14] [15] [16] . Collectively, these findings suggest that CT-1 may contribute to the development of hypertensive heart disease through both the induction of cardiomyocyte hypertrophy and the facilitation of myocardial fibrosis.
We thus have hypothesized first that CT-1 may be abnormally up-regulated in hypertensive patients, and secondly that this cytokine can be a marker of hypertensive heart disease. To test these two hypotheses, plasma levels of CT-1 were determined in normotensive subjects and hypertensive patients with and without LVH. In addition, the associations of plasma CT-1 with serum levels of the amino-terminal pro-brain natriuretic peptide (NT-proBNP) and the carboxy-terminal propeptide of procollagen type I (PICP), that have been proposed as markers of LVH [17] and myocardial fibrosis [18] , respectively, were also investigated.
Methods

Subjects
All subjects gave written informed consent to participate in the study and the institutional review committee approved the study protocol. The study conformed to the principles of the Helsinki Declaration. The study population consisted of 31 normotensive subjects and 111 hypertensive patients with sitting systolic and sitting diastolic blood pressure of more than 139 and 89 mmHg, respectively. Blood pressure was measured on three occasions using a mercury sphygmomanometer and the mean of these three readings was recorded. All patients had appropriate clinical and laboratory evaluation to exclude secondary hypertension and none of them had received previous treatment with antihypertensive drugs. Hypertensives were divided into two subgroups according to the presence or absence of LVH in the echocardiogram (see below). Whereas LVH was not detected in 54 patients, it was present in 57 patients. Other cardiac diseases associated with LVH (e.g. hypertrophic cardiomyopathy and aortic stenosis) were excluded on echocardiography. No patient exhibited clinical manifestations of ischaemic heart disease or heart failure, and systolic dysfunction was excluded by echocardiographic evaluation (see below).
Assessment of left ventricular mass and function
Two-dimensional echocardiographic imaging, targeted M-mode recordings and Doppler ultrasound measurements were obtained in each patient. Left ventricular mass was measured and left ventricular mass index (LVMI) was calculated as previously described [19] . The presence of LVH was established either when LVMI was > 111 g/m 2 for men and > 106 g/m 2 in women [20] . The following pulsed Doppler measurements of the mitral flow were obtained: maximum early transmitral velocity in diastole (V E ); maximum late transmitral velocity in diastole (V A ); the deceleration time of the early mitral filling wave (DT); and isovolumic relaxation time (IVRT). Left ventricular endocardial fractional shortening and ejection fraction (EF) were calculated according to Quinones et al. [21] . Left ventricular midwall fractional shortening (MWFS) was calculated according to de Simone et al. [22] . Systolic dysfunction was diagnosed when the EF and MWFS values were below 45% and/or 12%, respectively.
Measurement of plasma CT-1
We developed a novel enzyme-linked immunosorbent assay (ELISA) to measure plasma CT-1. An oligopeptide corresponding to amino acids 186-200 (SRTEGDLGQ-LLPGGS) of the human CT-1 was synthesized according to the Merrifield solid phase method [23] , using the Fmoc alternative [24] . There is no homology between this peptide and other cytokines of the interleukin-6 family. The peptide was further purified by high-performance liquid chromatography. The pure molecular mass was confirmed using matrix-assisted laser desorption mass spectrometry. Two rabbits were immunized by intradermal injection of 1ml of a 1 : 1 emulsion of complete Freund's adjuvant and saline solution containing 0.5 mg of the antigenic peptide and 0.5 mg of T helper determinant FIS [25] . Rabbits were boosted at days 30 and 45 with the same peptide mixture but emulsified in incomplete Freund's adjuvant by subcutaneous and intramuscular injections, respectively. At day 65, sera were drawn and antibodies were tested against peptide SRTEGDLGQLLPGGS and against human recombinant CT-1 by ELISA and Western blotting. The ELISA was performed as follows: dilutions of recombinant human CT-1 in buffer HNaCO 3 0.1 mol/l, pH ¼ 9.5 in a range from 0 to 1000 fmol used for the standard curve as well as 100 ml of plasma from each patient were incubated in 96-well microtiter plates (NUNC Maxisorp, Nunc, Denmark) at 48C overnight. Plates were washed three times with 250 ml/well of washing buffer (HNa 2 PO 4 80 mmol/l, H 2 NaPO 4 Á2H 2 O 25 mmol/l, NaCl 100 mmol/l (PBS) and 0.05% Tween 20, pH ¼ 7.5) and blocked with bovine serum albumin 5% in PBS for 2 h at room temperature (200 ml/well). Samples were then incubated with a polyclonal anti-CT-1 antibody at a 1 : 500 dilution in PBS at room temperature for 1 h (100 ml/well). After three additional washes with washing buffer, a biotin conjugated goat anti-rabbit IgG antibody (Amersham Biosciences, Piscataway, New Jersey, USA) was added at a 1 : 1000 dilution in PBS and incubated at room temperature for 1 h (100 ml/well). After three more washes, samples were incubated at 378C for 1 h with a streptavidin-horseradish-peroxidase conjugate (Amersham Biosciences) at a 1 : 500 dilution in PBS (100 ml/ well). Finally, plates were developed using TMB Substrate Reagent kit (Pharmingen, San Diego, California, USA) (100 ml/well) and the reaction was stopped with H 2 SO 4 2N (100 ml/well). The absorbance was read at 450 nm with a Multiskan Ascent (Thermo Labsystem software). In each experiment, a standard curve was performed ( Fig. 1 ) and the results were adjusted to Hill's equation:
In every experiment, all points (from the standard curve and serum samples) were measured in duplicate. The inter-assay and intra-assay coefficients of variations were 6.9 and 7.4%, respectively. The sensitivity was 2.9 fmol of CT-1/ml. Plasma concentration of CT-1 is expressed as fmol/ml.
Measurement of serum PICP and NT-proBNP PICP was determined in serum samples by radioimmunoassay according to a method previously described [26] . The inter-assay and intra-assay coefficients of variation were 7 and 3%, respectively. The sensitivity was 5 mg of PICP/l (or 50 pmol of PICP/l).
NT-proBNP was measured in serum samples by ELISA according to Karl et al. [27] . The inter-assay and intra-assay coefficients of variation were lower than 2%. The sensitivity was 5 pg of PICP/ml (or 0.590 pmol of PICP/ml).
Statistical analysis
Once normality was demonstrated (Shapiro-Wilks test), a Student's t-test was used to compare the group of normotensives and the whole group of hypertensives and the subgroup of hypertensives without LVH and the subgroup of hypertensives with LVH; otherwise the nonparametric Mann-Whitney's U test was employed. Categorical variables were analyzed by the chi-square (x 2 ) Fisher exact test when necessary. Correlations were estimated by Spearman's correlation coefficients. Partial correlation coefficients were calculated after adjustment for potential confounding factors (systolic blood pressure, LVMI). Receiver operating characteristic (ROC) curves allowed determination of the overall performance of CT-1 and NT-proBNP for predicting LVH in the whole population of subjects. Values are expressed as mean AE SEM. A value of P < 0.05 was considered statistically significant.
Results
Clinical and echocardiographic characteristics
Clinical and echocardiographic parameters evaluated in normotensives and hypertensives are presented in Table 1 . As expected, blood pressure values were significantly higher in hypertensives than in normotensives. In addition, the V E : V A ratio was significantly lower in hypertensives than in normotensives. No other significant differences between the two groups were observed in the remaining parameters. Table 2 shows the clinical and echocardiographic parameters assessed in the two sub-groups of hypertensives. Body mass index (BMI), systolic blood pressure (SBP) and pulse pressure (PP) were significantly higher in hypertensives with LVH than in hypertensives without LVH. Whereas the value of LVMI was significantly higher in hypertensives with LVH than in hypertensives without LVH, no other significant differences between Cardiotrophin-1 in hypertension Ló pez et al. 627 the two sub-groups were found in the remaining parameters.
Plasma concentration of CT-1 CT-1 immunoreactivity was detected in plasma from all the subjects studied. Plasma CT-1 was significantly increased in hypertensives compared with normotensives (Table 1) . Furthermore, CT-1 was increased in hypertensives with LVH compared with hypertensives without LVH (68.87 AE 7.59 versus 37.67 AE 2.27 fmol/ ml, P < 0.001) (Fig. 2) . Also 31 and 68% of hypertensives without and with LVH, respectively, exhibited values of CT-1 above the upper limit in controls (41 fmol/ml), this difference being statistically significant (P < 0.01).
Serum concentrations of PICP and NT-proBNP Serum PICP was significantly higher in hypertensives than in normotensives (Table 1 ). In addition, PICP was increased in hypertensives with LVH compared with hypertensives without LVH (119.30 AE 4.22 versus 99.87 AE 3.98 mg/l) (Fig. 2) .
The values of NT-proBNP were similar in hypertensives compared with normotensives (Table 1 ). In addition, no differences were found in NT-proBNP between hypertensives with and without LVH (49.42 AE 4.58 versus 49.63 AE 4.36 pg/ml) (Fig. 2) .
Associations of CT-1 with blood pressure, LVMI and PICP CT-1 directly correlated with systolic blood pressure (r ¼ 0.453, P < 0.001), LVMI (r ¼ 0.319, P < 0.001), and PICP (r ¼ 0.573, P < 0.001) in all subjects (Figs 3, 4 and 5, respectively). When we excluded the influence of systolic blood pressure in partial correlation analysis, the correlation between CT-1 and LVMI remained significant (r ¼ 0.234, P < 0.01). Similarly, when we excluded the influence of SBP or LVMI in partial correlation analysis, the correlation between CT-1 and PICP remained significant (r ¼ 0.436, P < 0.001). No other associations were found between CT-1 and the remaining parameters assessed in this study. 
Hypertensives
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Analysis of ROC curves
The ROC curves show the overall performance of CT-1 and NT-proBNP for predicting LVH (Fig. 6) . The area under the ROC curve was larger (P < 0.05) for CT-1 (0.78 AE 0.04) than for NT-proBNP (0.50 AE 0.05). Only the area under the ROC curve for CT-1 was higher (P < 0.001) than 0.50. From the ROC curves, cutoff values of reference for CT-1 and NT-proBNP were calculated. The sensitivity and specificity of each of these two values for predicting LVH are presented in Table 3 . Overall, the cutoff value of CT-1 showed better sensitivity and specificity. Thus, the relative risk of presenting LVH was higher for subjects with CT-1 values > 39 fmol/ml than for subjects with NT-proBNP values > 50 pg/ml (Table 3) .
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Discussion
The main findings of this study are as follows: (1) plasma concentrations of CT-1 are abnormally high in patients with essential hypertension, (2) an association exists between plasma CT-1 and LVMI and PICP in hypertensives; and (3) plasma CT-1 is more accurate than NT-proBNP in the discrimination of LVH in these patients.
Pathophysiological meaning
Several mechanisms may play a role in the observed increase of CT-1 in hypertension. Talwar et al. [28] reported that plasma levels of CT-1 increase in proportion to the trans-valvular aortic pressure gradient in patients with aortic stenosis. On the other hand, the progressive increase in left ventricular CT-1 expression seen with age in SHR parallels the progressive increase in arterial hypertension [10] . In addition, Pan et al. [29] reported increased CT-1 expression in the heart of rodent animals subjected to ligation of the abdominal aorta. Thus, pressure overload may stimulate cardiac CT-1, which is in accordance with our finding that a direct correlation exists between SBP and CT-1 in subjects from the present study. Alternatively, non-haemodynamic factors may also be involved in upregulation of CT-1. For example, the expression of CT-1 mRNA has been found to be stimulated by norepinephrine [30] and angiotensin II [31, 32] , in cultured cardiomyocytes and cardiac fibroblasts. In addition, genetic variants in the coding and promoter region of the human CT-1 gene have been recently described which might modify gene and protein expression and/or function [33] .
Our finding that plasma CT-1 correlates with LVMI expands previous findings by Tsutamoto et al. [34] showing a similar correlation in patients with dilated cardiomyopathy, thus suggesting that this cytokine plays a pathophysiological role in left ventricular growth response to either pressure or volume overload. Furthermore, our finding that one-third of the hypertensive patients without LVH exhibit abnormally high levels of CT-1 suggests that up-regulation of this cytokine precedes the development of cardiac growth in human hypertension. This possibility is in agreement with the finding by Ishikawa et al. [11] that a heart-specific increase in CT-1 gene expression precedes the establishment of LVH in SHR. It is likely that the excess of CT-1 plays a mechanistic role in the development and maintenance of hypertensive LVH. In fact, it has been shown that chronic administration of CT-1 to mice is associated with an increase in left ventricular weight to body weight ratio [9] . Furthermore, experiments performed in isolated rat ventricular cardiomyocytes show that CT-1 causes an increase in cell size through the interaction with the gp130/LIF receptor and the activation of both mitogen-activated protein kinase and Janus kinase signal transducers and activators of transcription signaling pathways [6, 7] . Fukuzawa et al. [35] have shown that CT-1 increased angiotensinogen mRNA expression in rat cardiomyocytes and that losartan attenuated CT-1 induced hypertrophy of these cells, suggesting that up-regulation of angiotensinogen and angiotensin II production contributes to the hypertrophic effect of CT-1.
The 100 kDa PICP is cleaved during the extracellular processing of procollagen type I into the fibril-forming collagen type I molecules [36] . The released peptide is found in an immunochemically intact form in blood. A number of studies performed in SHR [37] [38] [39] [40] [41] and hypertensive patients [19, 42, 43] show that the circulating level of PICP is associated with the extent of myocardial deposition of collagen type I fibers in hypertensive heart disease. In this context, findings reported here suggest that an excess of CT-1 may be related to an exaggerated collagen type I synthesis and deposition in the myocardium of hypertensive patients. Two observations support this possibility. First, treatment of cultured cardiac fibroblasts with CT-1 markedly stimulated [ 3 H]proline incorporation [14] and PICP release [16] . Second, CT-1 has been shown to initiate and sustain the fibrotic process that leads to infarct scar formation in rats [16] .
Clinical application LVH detected by electrocardiogram or echocardiogram is an established surrogate end point for cardiovascular prognosis, because evidence for continuous risk prediction, as well as documented graded benefits from reversal of LVH is now available [44] . In validation studies, the sensitivity of echocardiography to detect LVH has been high (85-100%), whereas that of electrocardiography has ranged from as high as 50% in severely diseased necropsy populations to as low as 6-17% in studies in Cornell and Framingham [45] . However, the accuracy and reproducibility of echocardiographic measurements are dependent on the operator's skills. Thus, the availability of additional methods to detect the presence of LVH may play a role in the initial clinical assessment of hypertensive patients.
In this conceptual framework, some findings reported here may be of interest. First, as shown by the ROC curve analysis, plasma CT-1 is a sensitive and specific parameter in the identification of echocardiographic LVH. Second, subjects with plasma concentrations of CT-1 > 39 fmol/ml have a six-fold higher probability of presenting with echocardiographic LVH than do subjects with plasma CT-1 below this value. Third, plasma CT-1 has higher performance for estimating echocardiographic LVH than NT-proBNP. Therefore, because the determination of plasma CT-1 is simple, reproducible and lowcost, it may be useful for selecting those hypertensives candidate to undergo an echocardiographic examination to confirm the presence of LVH.
Our results demonstrate that no association exists between LVH and serum NT-proBNP in hypertensives with normal systolic function. In addition, we found that NT-proBNP has a low performance for estimating LVH in these patients. Thus, our findings agree with data reported by Talwar et al. [46] showing that NT-proBNP remains a useful diagnostic aid for hypertensive heart disease only when left ventricular systolic dysfunction is present.
Limitations of the study Some limitations of this study should be acknowledged. First, the study involved a relatively small number of hypertensive patients. However, they were all nevertreated patients which allowed us to exclude any influence of the antihypertensive treatment on the assessed parameters, namely LVH [47] . Second, the ELISA method here reported to measure CT-1 is less sensitive than the radioimmunoassay [48] and the immunochemiluminometric assay [49] reported by others, but it is sensitive enough to detect significant differences in the plasma concentrations of CT-1 among the different groups and subgroups of our study. Third, although it has been shown that the heart secretes CT-1 via the coronary sinus into the peripheral circulation [48] , given the earlier evidence showing that CT-1 mRNA is expressed in other organs [3] , there may be additional potential sources of circulating CT-1.
In conclusion, for the first time, we show that plasma levels of CT-1 are abnormally increased in essential hypertension. In addition, we report that plasma levels of this cytokine are associated with the magnitude of left ventricular growth in hypertensive patients. Thus, the measurement of plasma CT-1 could be a practical and useful tool in the initial assessment of hypertensive heart disease. In particular, it might have clinical relevance in identifying those hypertensives susceptible to undergo further studies to identify LVH (i.e. echocardiography). Nevertheless, because of the limitations of this investigation, we are aware that further large studies are necessary to definitively validate this approach.
